1. Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137– 1146 (2007).
2. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405–413 (1994).
3. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).
4. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
5. Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 8, 1069–1086 (2018).
6. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
7. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 99, 12293–12297 (2002).
8. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
9. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
10. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
11. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
12. de Miguel, M. & Calvo, E. Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell 38, 326–333 (2020).
13. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).
14. Robert, C. et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J. Clin. Oncol. 36, 1668–1674 (2018).
15. Borghaei, H. et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non- Small-Cell Lung Cancer. J. Clin. Oncol. 39, 723–733 (2021).
16. Motzer, R. J. et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). J. Clin. Oncology 38, 617–617 (2020).
17. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N. Engl. J. Med. 378, 158–168 (2018).
18. Fessas, P. et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 159, 167–177 (2020).
19. Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 28, iv119–iv142 (2017).
20. Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).
21. Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 36, 1714–1768 (2018).
22. Zamami, Y. et al. Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis. JAMA Oncol 5, 1635–1637 (2019).
23. Mikami, T. et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J. Neurooncol. 152, 135–144 (2021).
24. Mehra, R. et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br. J. Cancer 119, 153–159 (2018).
25. Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915– 1928 (2019).
26. Kang, Y.-K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet 390, 2461–2471 (2017).
27. Motzer, R. J. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal- Cell Carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
28. Larkin, J. et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
29. Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).
30. Ricciuti, B. et al. Immune Checkpoint Inhibitor Outcomes for Patients With Non– Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J. Clin. Orthod. 37, 1927–1934 (2019).
31. Street, S. et al. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann. Oncol. (2021) doi:10.1016/j.annonc.2021.05.357.
32. Mazzarella, L. et al. The evolving landscape of “next-generation” immune checkpoint inhibitors: A review. Eur. J. Cancer 117, 14–31 (2019).
33. Nakamura, Y. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Front. Med. 6, 119 (2019).
34. Xu, Y., Fu, Y., Zhu, B., Wang, J. & Zhang, B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front. Immunol. 11, 2023 (2020).
35. Hasan Ali, O. et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur. J. Cancer 107, 8–14 (2019).
36. Yano, S. et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur. J. Cancer 130, 198–203 (2020).
37. Fujimura, T. et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget 9, 15542–15551 (2018).
38. Hopkins, A. M. et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br. J. Cancer 117, 913–920 (2017).
39. Martens, A. et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin. Cancer Res. 22, 2908–2918 (2016).
40. Weide, B. et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin. Cancer Res. 22, 5487–5496 (2016).
41. Khoja, L. et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 5, 2792–2799 (2016).
42. Diem, S. et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111, 176–181 (2017).
43. Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 6, 74 (2018).
44. Bagley, S. J. et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106, 1–7 (2017).
45. Daly, L. E. et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer 116, 310–317 (2017).
46. Diehl, A., Yarchoan, M., Hopkins, A., Jaffee, E. & Grossman, S. A. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8, 114268–114280 (2017).
47. Lalani, A.-K. A. et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6, 5 (2018).
48. Li, M. et al. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J. Cancer Res. Clin. Oncol. 145, 2541–2546 (2019).
49. Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non– Small-Cell Lung Cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
50. Garon, E. B. et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
51. Motzer, R. J. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
52. Ferris, R. L. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 375, 1856–1867 (2016).
53. Haratani, K. et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer. JAMA Oncol 4, 374–378 (2018).
54. Ishihara, H. et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol. Oncol. 37, 355.e21-355.e29 (2019).
55. Pavan, A. et al. Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non ‐ Small Cell Lung Cancer Treated with Immune ‐ Checkpoint Inhibitors. The Oncologist vol. 24 1128–1136 (2019).
56. Coutzac, C. et al. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD- 1 Blockade Induce Distinct Immunopathological Entities. J. Crohns. Colitis 11, 1238– 1246 (2017).
57. Tanaka, K. et al. Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget 9, 30587–30593 (2018).
58. Yoshino, K., Nakayama, T., Ito, A., Sato, E. & Kitano, S. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1- dominant immune response in immune-related adverse events: two case reports. BMC Cancer 19, 1019 (2019).
59. Wang, D. Y. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 4, 1721–1728 (2018).
60. Fujisawa, Y. et al. Fluctuations in routine blood count might signal severe immune- related adverse events in melanoma patients treated with nivolumab. J. Dermatol. Sci. 88, 225–231 (2017).
61. Ishikawa, N., Hattori, N., Yokoyama, A. & Kohno, N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Investig. 50, 3–13 (2012).
62. Haslam, A., Gill, J. & Prasad, V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open 3, e200423 (2020).
63. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
64. Tuchendler, E., Tuchendler, P. K. & Madej, G. Immunodeficiency caused by cirrhosis. Clin Exp Hepatol 4, 158–164 (2018).
65. Albillos, A., Lario, M. & Álvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 61, 1385–1396 (2014).
66. Irvine, K. M., Ratnasekera, I., Powell, E. E. & Hume, D. A. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front. Immunol. 10, 293 (2019).
67. Morita, R. et al. Real-world effectiveness and safety of nivolumab in patients with non- small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer 140, 8–18 (2020).
68. Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J. Clin. Oncol. 33, 550 (2015).
69. Edeline, J. et al. A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver Int. 36, 1821–1828 (2016).
70. Hiraoka, A. et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer 6, 204–215 (2017).
71. McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat. Rev. 39, 534–540 (2013).
72. Bullock, A. F., Greenley, S. L., McKenzie, G. A. G., Paton, L. W. & Johnson, M. J. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur. J. Clin. Nutr. 74, 1519–1535 (2020).
73. Shoji, F. et al. Pretreatment prognostic nutritional index as a novel biomarker in non- small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 136, 45–51 (2019).
74. Matsubara, T. et al. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. J. Thorac. Dis. 12, 1520–1528 (2020).
75. Peng, L. et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol. Immunother. 69, 1813–1822 (2020).
76. Pinato, D. J. et al. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers 12, (2020).
77. Lebossé, F. et al. CD8+ T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine 49, 258– 268 (2019).
78. Yang, J., Shord, S., Zhao, H., Men, Y. & Rahman, A. Are hepatic impairment studies necessary for therapeutic proteins? Clin. Ther. 35, 1444–1451 (2013).
79. Cosson, V. F., Ng, V. W., Lehle, M. & Lum, B. L. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother. Pharmacol. 73, 737–747 (2014).
80. Wang, W., Wang, E. Q. & Balthasar, J. P. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics. Clinical Pharmacology & Therapeutics vol. 84 548–558 (2008).
81. Kamath, A. V. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discovery Today: Technologies vols. 21–22 75–83 (2016).
82. Sun, Q., Seo, S., Zvada, S., Liu, C. & Reynolds, K. Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies? Clin. Pharmacol. Ther. 107, 1256–1262 (2020).
83. Yoneshima, Y. et al. Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer 130, 5–9 (2019).
84. Shiroyama, T. et al. Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci. Rep. 9, 2447 (2019).
85. Roch, B. et al. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143, 19–26 (2020).
86. Takada, K. et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer 145, 18–26 (2020).